Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02600949 · ClinicalTrials.gov registry record · Phase 1
Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer
A Phase 1 study of Metastatic Pancreatic Ductal Adenocarcinoma and Metastatic Colorectal Adenocarcinoma, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- Phase 1
- Development phase
- 117
- Enrollment target
- 1
- Study location
NCT02600949: Active Phase 1 study of Metastatic Pancreatic Ductal Adenocarcinoma and Metastatic Colorectal Adenocarcinoma, sponsored by M.D. Anderson Cancer Center.
NCT02600949 is a Phase 1 study of Metastatic Pancreatic Ductal Adenocarcinoma and Metastatic Colorectal Adenocarcinoma that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 117 participants, below the 179-participant average among 20 other Metastatic Pancreatic Ductal Adenocarcinoma trials with a reported enrollment target (35% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02600949, a Phase 1 study of Metastatic Pancreatic Ductal Adenocarcinoma and Metastatic Colorectal Adenocarcinoma, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 117 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase I trial studies the side effects and best way to give personalized peptide vaccine in patients with pancreatic or colorectal cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment (advanced). Personalized peptide vaccine is a vaccine developed from patient's own tumor cells and blood in order to use as a biological therapy. Biological therapies, such as personalized peptide vaccine may attack tumor cells and stop them from growing or kill them.
Conditions Studied
Interventions
- BIOLOGICAL Pembrolizumab
- PROCEDURE Computed Tomography
- DRUG Imiquimod
- BIOLOGICAL Sotigalimab
- BIOLOGICAL Synthetic Tumor-Associated Peptide Vaccine Therapy
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 117 participants |
| Start Date | 2016-05-11 |
| Est. Completion | 2027-05-31 |
| Phase | Phase 1 |
What the registry record for NCT02600949 still lists
NCT02600949 is an interventional study that assigns participants to a tested intervention. The registered 117 participants enrollment target is mid-sized for trials with a published cap, below the 179-participant average among 20 other Metastatic Pancreatic Ductal Adenocarcinoma trials with a reported enrollment target (35% lower).
The record links to 6 conditions, with Metastatic Pancreatic Ductal Adenocarcinoma appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT02600949 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT02600949 about?
NCT02600949 is a clinical study titled "Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer". This phase I trial studies the side effects and best way to give personalized peptide vaccine in patients with pancreatic or colorectal cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment (advanced). Personalized peptide vaccine is a vaccine de...
What is the current status of trial NCT02600949?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 117 participants. The study started on 2016-05-11. Estimated completion is 2027-05-31.
What conditions does trial NCT02600949 study?
This clinical trial studies the following conditions: Metastatic Pancreatic Ductal Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v6 and v7, Stage IV Colorectal Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7.
What interventions are being tested in trial NCT02600949?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Computed Tomography (PROCEDURE), Imiquimod (DRUG), Sotigalimab (BIOLOGICAL), Synthetic Tumor-Associated Peptide Vaccine Therapy (BIOLOGICAL).
Who is sponsoring clinical trial NCT02600949?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02600949 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Pancreatic Ductal Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02600949's enrollment target sits among peer trials
117 5th of 20 higher than 16 of 20 other Metastatic Pancreatic Ductal Adenocarcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Pancreatic Ductal Adenocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
RECRUITING · Phase 1
-
Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma
RECRUITING · Phase 1
-
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
RECRUITING · Phase 1
-
CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer
RECRUITING · Phase 1
-
MK2 Inhibitor in Combination With mFOLFIRINOX for Untreated Metastatic Pancreatic Ductal Adenocarcinoma
RECRUITING · Phase 1
-
Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC)
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03539822 · 117 participants · Phase 1
Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies
- NCT03786692 · 117 participants · Phase 2
Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC
- NCT04479696 · 117 participants · NA
Customized Neuro-Imaging Referenced Symptom Video for the Reduction of Patient and Caregiver Anxiety Around Radiation Treatment for Brain Tumors
- NCT04940585 · 117 participants · NA
ROSE in Sunset Park
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI